Abstract
Adenoviruses are widely used as vectors to deliver genetic material into cells. Although these vectors are currently the most efficient vectors used, they are not specific and not efficient enough to result in a good clinical outcome in the treatment against cancer. To increase the specificity, a transgene can be placed under the control of a tumor specific promoter, such as the epithelial glycoprotein-2 (EGP2) promoter. This promoter is active in a broad range of epithelial derived cancers. The length of the EGP2 promoter fragment used in initial studies is 3.4 kb. This promoter fragment showed in adenoviral context high activity and selectivity when tested both in vitro and in vivo. However due to limited space in the adenoviral genome, this promoter fragment is too large for the incorporation of several expression cassettes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
